Indometacin Sintofarm (Indometacin)

Indometacin blocks the cyclooxygenase enzymes COX‑1 and COX‑2, which are required for the production of prostaglandins. By lowering prostaglandin levels, it diminishes inflammation, pain, and fever associated with various musculoskeletal and rheumatic conditions.

The specific dose and frequency of Indometacin Sintofarm are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. The product is supplied as a rectal suppository, and the prescriber will provide individualized dosing instructions.

The safety of indometacin during pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indometacin is a potent non‑selective NSAID with strong anti‑inflammatory activity, often considered more effective for gout flares than some other NSAIDs. However, its gastrointestinal and renal risk profile may be higher, so clinicians balance efficacy against safety when choosing an alternative.

Indometacin Sintofarm suppositories should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

The medication is supplied as a rectal suppository. The patient inserts the suppository into the rectum, preferably after bowel movements, and holds it in place for the time indicated by the prescriber to allow complete absorption.

Serious risks include gastrointestinal ulceration or bleeding, severe kidney injury, liver toxicity, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or anaphylaxis. Patients should be monitored for signs of these events and seek immediate medical attention if they occur.

Indometacin should be avoided in individuals with known hypersensitivity to indometacin or other NSAIDs, active gastrointestinal ulcer disease, severe renal or hepatic impairment, and in patients taking anticoagulants or other NSAIDs without medical supervision.